International Journal of Cardiology
Volume 127, Issue 1 , Pages 1-4 , 23 June 2008

Hypertrophic cardiomyopathy is a global disease including China

Received 6 July 2007 ,Accepted 6 July 2007.

References 

  1. Liouville H. Retrecissement cardiaque sous aortique. Gaz Med Paris. 1869;24:161
  2. Hallopeau L. Retrecissement ventriculo-aortique. Gaz Med Paris. 1869;24:683
  3. Schmincke A. Ueber linksseitige muskulose conusstenosen. Dtsch Med Woehenschr. 1907;33:2082
  4. Acierno LJ. The history of cardiology. London: The Parthenon Publishing Group; 1994;78
  5. Brock RC. Functional obstruction of the left ventricle. Guy Hosp Rep. 1957;106:221–238
  6. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1–8
  7. Maron BJ. Hypertrophic cardiomyopathy: an important global disease. Am J Med. 2004;116:63–65
  8. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116:14–18
  9. Ho HH, Lee KLF, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med. 2004;116:19–23
  10. Cheng TO. Cardiology in People's Republic of China — Paul D. White lecture. In:  Russek HI editors. New Horizons in Cardiovascular Practice. Baltimore: University Park Press; 1975;p. 1–27
  11. Cheng TO. Hypertrophic cardiomyopathy in China: three decades of progress. Int J Cardiol. 2005;100:493–494
  12. Shanghai First Medical University Zhong Shan Hospital , Shanghai Institute of Cardiovascular Diseases . Clinical investigation of 74 cases of primary cardiomyopathy: II. Obstructive and restrictive primary cardiomyopathy. Chin J Intern Med. 1977;16:340–346
  13. Fang WH, Guo HS, Tao P, Wang SH from the Cardiovascular Institute, Chinese Academy of Medical Sciences. Discussion about some questions on the diagnosis of hypertrophic cardiomyopathy. An analysis of 44 cases of angiographically confirmed cases. Chin J Intern Med. 1982;21:596–599
  14. Chinese Society of Cardiology . Editorial Board of Chinese Journal of Cardiology: a report of 3rd Chinese Conference on Myocarditis and Cardiomyopathy. Chin J Cardiol. 2007;35:3–4
  15. Chinese Society of Cardiology . Editorial Board of Chinese Journal of Cardiology, “Consensus on Diagnosis and Treatment of Cardiomyopathies” Chinese Expert Panel: recommendations on diagnosis and treatment of cardiomyopathies. Chin J Cardiol. 2007;35:5–16
  16. Xie MX, Wang XF, Cheng TO, Lu Q, Yuan L, Lou X. Real-time 3-dimensional echocardiography: a review of the development of the technology and its clinical application. Progr Cardiovasc Dis. 2005;48:209–225
  17. Cheng TO. Clinical application of real-time three-dimensional echocardiography. J Cardiol. 2007;49:213–214
  18. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006;113:e858–e862
  19. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785
  20. Song L, Zou Y, Wang J, et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clin Chim Acta. 2005;351:209–216
  21. Liao YH. From etiological research to clinical diagnosis and therapeutic practice in cardiomyopathies. Chin J Cardiol. 2007;35:1–2
  22. Cheng TO. Prevalence of hypertrophic cardiomyopathy in China. Chin Med J. 2004;117:1600
  23. Cheng TO. Frequency of cardiac troponin I mutations in families with hypertrophic cardiomyopathy in China. J Am Coll Cardiol. 2005;46:180–181
  24. Wang SX, Zou YB, Fu CY, Wang H, Wang JZ, Song XD, et al. Clinical features of dilated cardiomyopathy-like hypertrophic cardiomyopathy caused by 13261G>A mutation in cardiac myosin-binding protein C gene. Chin J Cardiol. 2007;35:17–20
  25. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211–214
  26. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet. 2000;355:425–426
  27. Li ZQ, Cheng TO, Zhang WW, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. The Chinese experience in 119 patients from a single center. Int J Cardiol. 2004;93:197–202
  28. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol. 2003;42:1687–1713
  29. Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy. Alive and quite well. Circulation. 2005;111:2016–2018
  30. Cheng TO. Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol. 1997;20:667
  31. Cheng TO. Time for a prospective national or international registry. Catheter Cardiovasc Diagn. 1997;42:234
  32. Cheng TO. Transcatheter alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Circulation. 1999;100:1252
  33. Hui RT. Contemporary diagnosis and treatment of hypertrophic cardiomyopathy. Chin J Cardiol. 2007;35:82–85
  34. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA. 2002;287:1308–1320

PII: S0167-5273(07)01697-X

doi: 10.1016/j.ijcard.2007.07.165

International Journal of Cardiology
Volume 127, Issue 1 , Pages 1-4 , 23 June 2008

Article Tools

* Image Usage & Resolution